10x Genomics (TXG) Current Assets (2018 - 2026)

10x Genomics (TXG) has 9 years of Current Assets data on file, last reported at $669.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 15.52% year-over-year to $669.7 million; the trailing twelve-month figure through Mar 2026 stood at $669.7 million (up 15.52% YoY), and the FY2025 full-year result was $684.5 million, up 17.12% from the prior year.
• Current Assets slipped to $669.7 million in Q1 2026, from $684.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $697.3 million in Q1 2022 to a low of $562.3 million in Q3 2023.
• A 5-year average of $620.3 million and a median of $601.9 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slipped 15.41% in 2022 and rose 17.12% in 2025, its largest moves.
• Tracing TXG's Current Assets over 5 years: stood at $635.0 million in 2022, then retreated by 6.14% to $596.0 million in 2023, then decreased by 1.95% to $584.4 million in 2024, then climbed by 17.12% to $684.5 million in 2025, then decreased by 2.15% to $669.7 million in 2026.
• Business Quant data shows TXG's Current Assets at $669.7 million in Q1 2026, $684.5 million in Q4 2025, and $659.8 million in Q3 2025.